To the Editor: The ABCD rule (A for asymmetric shape, B for irregular borders, C for variation in color, and D for diameter [6 mm) has been proposed as a reliable and affordable screening method in melanoma campaigns. 1, 2 However, little is known about the ability of examiners to agree on ABC parameters when faced with pigmentary lesions. 3 We designed a study to separately analyze judgments on ABC features, avoiding, as much as possible, the influence of the potentially confounding effect of the observer's overall diagnostic impression.
Twelve photographs of melanocytic nevi and 11 photographs of melanomas with Breslow thickness #1.5 mm were randomly selected from our file of excised lesions. For judgment regarding symmetry and borders, the profiles of the selected lesions were traced, and the resultant silhouette was filled in with black. To minimize the effect of dimension Example of test materials prepared for the ABC (asymmetry, border, color) perception exercise. A, Symmetry and borders were evaluated using a black colored-in blot representing the shape of the segmented lesion. B, Judgment of color was performed using an ovoid depiction of the original segmented lesion. C, Original clinical photographs were used for the final classification of lesions as melanocytic nevi or melanoma.
on the judgment, all silhouettes were given the same area. For judgment regarding color, the borders of the original photographs were concealed and the lesions were given a regular circular border (Fig 1) .
We organized 2 evaluation sessions involving 7 experienced dermatologists 3 weeks apart from each other. We projected slides obtained from the test material and asked participants to independently express their judgment on symmetry, border, and color with dichotomous answers (eg, color mainly homogeneous or nonhomogeneous). We also organized a third session during which the original clinical photographs were shown and participants were asked to classify lesions as melanocytic nevi or melanoma. Cohen kappa and Fleiss kappa 4 were used to assess intraobserver and interobserver agreement with multiple raters, respectively. The relation between the scores on ABC parameters and the final diagnosis reached by dermatologists (ie, nevus vs melanoma) was examined by logistic regression analysis and expressed as odds ratios (ORs) with their 95% confidence intervals (CI).
Variations were observed for intraobserver agreement on ABC parameters. The judgments on borders had the highest values of agreement, with Cohen kappa ranging 0.64-1.00. Less satisfactory was the intraobserver agreement for judgment on symmetry and color, Cohen kappa ranging 0.38-0.81 for symmetry and 0.26-0.72 for color. Table I presents data on interobserver agreement. The agreement was moderate to substantial for judgment on borders and for the final diagnosis made by the dermatologists. On the basis of logistic regression analysis, a diagnosis of melanoma was significantly associated with judgment of irregular borders (OR 2.4, 95% CI 1.1-5.4) and haphazard color (OR 2.6, 95% CI 1.4-4.8) but not with judgment of asymmetric lesion (OR 1.3, 95% CI 0.6-2.9).
Our data point to the existence of variability in the interpretation of ABC parameters. We documented high interobserver agreement on the final diagnosis in the face of unsatisfactory intraobserver and interobserver agreement on specific features. Even if not a direct proof of the cognitive mechanism involved, our data support the concept of an automatic pattern recognition modality in the diagnosis of pigmentary lesions. 5 They also point to the need for a more standardized terminology to describe the clinical features of pigmented lesions. 6 We wish to thank Gillian Jarvis for editorial assistance. 2 it is possible that insurance status has contributed to the later-stage diagnoses and consequent poorer outcomes of melanoma in minority patients. This analysis considers the effect of race and insurance status on melanoma stage at diagnosis and uniquely emphasizes the significant association of Medicaid with latestage diagnoses within a single race.
We performed an epidemiological assessment of 26,958 patients with cutaneous melanoma by using the Ohio Cancer Incidence Surveillance System registry from 1996 to 2009. The cancer incidence data used in these analyses were obtained from the Ohio Department of Health's Ohio Cancer Incidence Surveillance System, which is a cancer registry partially supported by the National Program of Cancer Registries at the Centers for Disease Control and Prevention through cooperative agreement 1U58DP003936-01. Use of these data does not imply that the Ohio Department of Health and Centers for Disease Control and Prevention agree or disagree with the analyses, interpretations, or conclusions in this article.
We collected information on insurance status ( primary payer at diagnosis), race, and stage at diagnosis. Chi-square analyses were performed and risk ratios were determined with a significance of P of less than .05. The categories of race for the chisquare analyses were white, black, and other (''other'' included Asian/Pacific Islander, American Indian, and other race entries in the database).
Chi-square analysis revealed a statistically significant relationship between insurance status and race (P \ .001) (Fig 1) . The proportions of race differed significantly within Medicaid (P \ .001) and private insurance (P ¼ .025).
Black patients were more likely to present at a late stage, which included stage III or IV at diagnosis (P \.001) (Table I) . Further, patients with Medicaid were significantly more likely to present at a late stage compared with patients with other insurance types, including those who were uninsured (P \.001). Of note, patients with Medicaid remained significantly more likely to present at a late stage (P \ .001) compared with patients in all insurance status categories when only white patients were considered (Table I) .
These findings suggest that insurance type alone, specifically Medicaid, may be involved in the disparities of melanoma stage at diagnosis. Potential explanations for this are decreased utilization of cancer screening in Medicaid subscribers and provider discrimination based on insurance status. Prior research has shown that Medicaid patients face lower acceptance rates for dermatology appointments (32% acceptance for those with Medicaid, 85% for those with Medicare, and 87% for those with private insurance) and longer wait times (50 days average for those with Medicaid and 37 days average for those with Medicare and private insurance), 3 possibly contributing to poorer outcomes.
A limitation of our study is that the data do not incorporate changes in insurance status before or after the time of diagnosis, given that length of time enrolled in Medicaid has been shown to be a significant variable affecting melanoma stage at diagnosis. 4 Patients with cancer who are on Medicaid have been shown to have comparatively later-stage diagnoses, 5 but few studies have considered patients with melanoma specifically. This study provides evidence that insurance type alone is associated with stage at melanoma diagnosis. Given that a larger proportion of patients from minority populations have Medicaid, 2 it is likely that insurance status is contributing to the current racial disparities in melanoma outcomes. In light of the frequently debated and shifting configuration of health insurance in this country, it is important that providers 
